Theravance Biopharma (TBPH) EBITDA Margin Growth (5y) (2018 - 2026)
Theravance Biopharma (TBPH) EBITDA Margin Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45,651.00 |
| Mar 31, 2026 | 53,485.00 |
| Dec 31, 2025 | 45,199.00 |
| Sep 30, 2025 | 38,736.00 |
| Jun 30, 2025 | 47,051.00 |
| Mar 31, 2025 | 27,110.00 |
| Dec 31, 2024 | -1,965.00 |
| Sep 30, 2024 | 46,043.00 |
| Jun 30, 2024 | -3,150.00 |
| Mar 31, 2024 | 130,276.00 |
| Dec 31, 2023 | 36,240.00 |
| Sep 30, 2023 | 43,063.00 |
| Jun 30, 2023 | 9,020.00 |
| Mar 31, 2023 | 54,191.00 |
| Dec 31, 2022 | 163,462.00 |
| Sep 30, 2022 | 125,982.00 |
| Jun 30, 2022 | 161,258.00 |
| Mar 31, 2022 | 161,393.00 |
| Dec 31, 2021 | 64,026.00 |
| Sep 30, 2021 | -23,077.00 |